dinaline

12/01/1985 - "The present paper describes 4-amino-N-(2'-aminophenyl)benzamide (GOE1734) with regard to synthesis; toxicity in mice, rats, and dogs; and differential therapeutic efficacy in slowly and rapidly proliferating rat tumors. "
12/01/1991 - "Dinaline significantly reduced the occurrence of malignant tumors in male rats and prolonged the manifestation time of malignancies in female rats. "
02/01/2018 - "Tumor-bearing nude rats were treated with Rpx, gemcitabine (GEM) or dinaline (DIN) as single agents, or a combination of Rpx with GEM, or DIN. "
06/01/2008 - "N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. "
01/01/2001 - "CI-994 (N-acetyl dinaline, PD 123654) is a novel oral agent active in a broad variety of murine and human tumor xenografts. "

06/01/2008 - "CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo."
07/01/1993 - "The efficacy and toxicity of Acetyldinaline for remission-induction treatment of leukemia were evaluated and compared with those observed in previous studies of Dinaline in the Brown Norway acute myelocytic leukemia, as a preclinical model for human acute myelocytic leukemia. "
04/01/1988 - "The efficacy and toxicity of Dinaline (GOE 1734; PD 104 208; NSC 328786; 4-amino-N-(2'-aminophenyl)benzamide) was evaluated in the Brown Norway acute myelocytic leukemia, which is generally accepted as a relevant preclinical model for human acute myelocytic leukemia. "

10/01/1996 - "Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro."
10/01/1996 - "Dinaline [4-amino-N-(2'-aminophenyl)-benzamide, Din], p-N-methyldinaline (Me-Din) and p-N-acetyldinaline (Ac-Din) were evaluated for their antineoplastic efficacy in acetoxymethylmethylnitrosamine-induced colorectal carcinomas in Sprague-Dawley rats and in two human colon cancer cell lines. "

11/01/1995 - "Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro."
11/01/1995 - "The human colon carcinoma cell line SW707 was incubated with different concentrations (7 microM - 540 microM) of the novel antineoplastic drug 4-amino-N(2'-aminophenyl)benzamide (GOE1734, dinaline) to study the effects on 3H-alpha-aminoisobutyric acid (AIB) - and 14C-methionine uptake as well as on 3H-thymidine incorporation into DNA. "
11/01/1995 - "Taken together, the results show that SW707 colon carcinoma cells exposed to dinaline demonstrate distinct but reversible changes in amino acid transport, protein metabolism, DNA synthesis and cell proliferation, thus giving a correlation with observations in vivo."
01/01/1995 - "The human colon carcinoma cell line SW 707 was exposed for up to 72 h to the new antineoplastic agent 4-amino-N-(2'-aminophenyl)benzamide (GOE 1734, dinaline). "
01/01/1996 - "Up to 4 h after treatment of human SW 707 colon carcinoma cells with the antineoplastic drug 4-amino-N-(2'-aminophenyl)-benzamide (GOE 1734, dinaline), the effects of tumour cell metabolism and proliferation were examined in vitro. "

04/01/1988 - "Dinaline: a new oral drug against leukemia? "
07/01/1993 - "The efficacy and toxicity of Acetyldinaline for remission-induction treatment of leukemia were evaluated and compared with those observed in previous studies of Dinaline in the Brown Norway acute myelocytic leukemia, as a preclinical model for human acute myelocytic leukemia. "